trial · primary record
Nerandomilast
Idiopathic Pulmonary Fibrosis
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 1666 |
| Primary completion | 2027-05-07 |
| Primary endpoint | Occurrence of any adverse event over the course of the extension trial (yes/no) i.e. up until the follow-up/end of study visit planned at the latest at week 99 |
| Registry ID | NCT06238622 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:43:51.697Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06238622
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- NERANDOMILAST · approval
- NERANDOMILAST · approval
- Nerandomilast · compound